These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15557199)
1. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. Morimoto J; Yoneyama H; Shimada A; Shigihara T; Yamada S; Oikawa Y; Matsushima K; Saruta T; Narumi S J Immunol; 2004 Dec; 173(11):7017-24. PubMed ID: 15557199 [TBL] [Abstract][Full Text] [Related]
2. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. Christen U; McGavern DB; Luster AD; von Herrath MG; Oldstone MB J Immunol; 2003 Dec; 171(12):6838-45. PubMed ID: 14662890 [TBL] [Abstract][Full Text] [Related]
4. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice. Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021 [TBL] [Abstract][Full Text] [Related]
5. Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-gamma-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics. Ejrnaes M; Videbaek N; Christen U; Cooke A; Michelsen BK; von Herrath M J Immunol; 2005 Mar; 174(5):2746-55. PubMed ID: 15728483 [TBL] [Abstract][Full Text] [Related]
6. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Frigerio S; Junt T; Lu B; Gerard C; Zumsteg U; Holländer GA; Piali L Nat Med; 2002 Dec; 8(12):1414-20. PubMed ID: 12415259 [TBL] [Abstract][Full Text] [Related]
7. Gut dysbiosis promotes islet-autoimmunity by increasing T-cell attraction in islets via CXCL10 chemokine. Pöysti S; Silojärvi S; Brodnicki TC; Catterall T; Liu X; Mackin L; Luster AD; Kay TWH; Christen U; Thomas HE; Hänninen A J Autoimmun; 2023 Nov; 140():103090. PubMed ID: 37572540 [TBL] [Abstract][Full Text] [Related]
8. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Uno S; Imagawa A; Saisho K; Okita K; Iwahashi H; Hanafusa T; Shimomura I Endocr J; 2010; 57(11):991-6. PubMed ID: 20966598 [TBL] [Abstract][Full Text] [Related]
9. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. Gallichan WS; Balasa B; Davies JD; Sarvetnick N J Immunol; 1999 Aug; 163(3):1696-703. PubMed ID: 10415077 [TBL] [Abstract][Full Text] [Related]
10. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. Yoneyama H; Narumi S; Zhang Y; Murai M; Baggiolini M; Lanzavecchia A; Ichida T; Asakura H; Matsushima K J Exp Med; 2002 May; 195(10):1257-66. PubMed ID: 12021306 [TBL] [Abstract][Full Text] [Related]
11. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Baker MS; Chen X; Rotramel AR; Nelson JJ; Lu B; Gerard C; Kanwar Y; Kaufman DB Surgery; 2003 Aug; 134(2):126-33. PubMed ID: 12947308 [TBL] [Abstract][Full Text] [Related]
12. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. Oikawa Y; Shimada A; Kasuga A; Morimoto J; Osaki T; Tahara H; Miyazaki T; Tashiro F; Yamato E; Miyazaki J; Saruta T J Immunol; 2003 Dec; 171(11):5865-75. PubMed ID: 14634096 [TBL] [Abstract][Full Text] [Related]
13. NK T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. Laloux V; Beaudoin L; Jeske D; Carnaud C; Lehuen A J Immunol; 2001 Mar; 166(6):3749-56. PubMed ID: 11238616 [TBL] [Abstract][Full Text] [Related]
14. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. Trembleau S; Penna G; Gregori S; Giarratana N; Adorini L J Immunol; 2003 Jun; 170(11):5491-501. PubMed ID: 12759426 [TBL] [Abstract][Full Text] [Related]
15. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. Rothe H; Hausmann A; Casteels K; Okamura H; Kurimoto M; Burkart V; Mathieu C; Kolb H J Immunol; 1999 Aug; 163(3):1230-6. PubMed ID: 10415018 [TBL] [Abstract][Full Text] [Related]
16. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. Whiting D; Hsieh G; Yun JJ; Banerji A; Yao W; Fishbein MC; Belperio J; Strieter RM; Bonavida B; Ardehali A J Immunol; 2004 Jun; 172(12):7417-24. PubMed ID: 15187119 [TBL] [Abstract][Full Text] [Related]
17. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. Klein RS; Izikson L; Means T; Gibson HD; Lin E; Sobel RA; Weiner HL; Luster AD J Immunol; 2004 Jan; 172(1):550-9. PubMed ID: 14688366 [TBL] [Abstract][Full Text] [Related]
18. Significance of serum CXCL10/IP-10 level in type 1 diabetes. Shigihara T; Oikawa Y; Kanazawa Y; Okubo Y; Narumi S; Saruta T; Shimada A J Autoimmun; 2006 Feb; 26(1):66-71. PubMed ID: 16309891 [TBL] [Abstract][Full Text] [Related]
19. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. Liu MT; Keirstead HS; Lane TE J Immunol; 2001 Oct; 167(7):4091-7. PubMed ID: 11564831 [TBL] [Abstract][Full Text] [Related]